CONCENTRATION OF RISK

9 Months Ended

Sep. 30, 2012

Risks and Uncertainties [Abstract]

Concentration Risk Disclosure [Text Block]

CONCENTRATION OF RISK

Customer and Credit Risk

The Company provides trade credit to its customers in the normal course of business.  

One payor accounted for approximately 20% and 13% of revenue during the three months ended September 30, 2012 and 2011, respectively, and approximately 18% and 13% of revenue during the nine months ended September 30, 2012 and 2011, respectively. The majority of the revenue is related to the Infusion Services segment.

Therapy Revenue Risk

The Company sells products related to the Immune Globulin (IVIG) therapy, which represented 18% and 25% of revenue during the three months ended September 30, 2012 and 2011, respectively and 20% and 26% of revenue during the nine months ended September 30, 2012 and 2011, respectively. The revenue is related to the Infusion Services segment.